ABVD, the Stanford V regimen, and BEACOPP for Hodgkin's lymphoma: What should an oncologist do?

Clinical Lymphoma

Volumn 6, Issue 1, 2005, Pages 50-51

  Connors, Joseph M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; VINCRISTINE;

ACUTE TOXICITY; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC TOXICITY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; EARLY MENOPAUSE; HODGKIN DISEASE; HUMAN; INFERTILITY; LEUKEMIA; LEUKEMOGENESIS; MEDICAL SPECIALIST; NOTE; ONCOLOGY; PROGNOSIS; SOLID TUMOR; STANDARDIZATION; SURVIVAL RATE; CANCER CONTROL; CANCER MORTALITY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE CALCULATION; DRUG EFFICACY; DRUG INDICATION; EVIDENCE BASED MEDICINE; FEMALE INFERTILITY; MALE INFERTILITY; MAXIMUM PERMISSIBLE DOSE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 22944469134     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2005.n.028     Document Type: Note

References (9)

1. Horning SJ, Hoppe RT, Advani R, et al. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: mature data in early and advanced stage patients. Blood 2004; 104(suppl):92a (Abstract #308).
2. Diehl V, Brillant C, Franklin J, et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9- and HD12- trials of die German Hodgkin Study Group (GHSG). Blood 2004; 104(suppl):91a (Abstract #307).
3. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21:607-614.
4. Canellos Gp, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478-1484.
5. Federico M, Levis A, Luminari S, et al. ABVD vs. STANFORD V (SV) vs. MOPP-EBV-CAD (MEC) in advanced Hodgkin's lymphoma. Final results of the IIL, HD9601 randomized trial. J Clin Oncol 2004; 22(suppl):559s (Abstract #6507).
6. Bartlett NL, Rosenberg SA, Hoppe RT, et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995; 13:1080-1088.
7. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348:2386-2395.
8. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506-1514.
9. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36:252-259.